EICHOR
● Active Not Recruiting
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non-Hodgkin · Refractory B-Cell NHL · Relapsed B-cell NHL · Sponsor: Janssen Research & Development, LLC
About this study
The main purpose of this study is to characterize safety and to determine the recommended phase 2 dose (RP2D) for JNJ-88998377 (Part A: Dose Escalation), to further assess the safety of JNJ-88998377 at the RP2D (Part B: Dose Expansion).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (19)
| Beijing Cancer Hospital | Beijing, China | — |
| Sun Yat Sen University Cancer Center | Guangzhou, China | — |
| The First Affiliated Hospital Zhejiang University College of Medicine | Hangzhou, China | — |
| Fudan University Shanghai Cancer Center | Shanghai, China | — |
| Tianjin Medical University Cancer Institute and Hospital | Tianjin, China | — |
| A O U Sant Orsola Malpighi | Bologna, Italy | — |
| National Cancer Center Hospital | Chūōku, Japan | — |
| National Cancer Center Hospital East | Kashiwa, Japan | — |
| The Cancer Institute Hospital of JFCR | Tokyo, Japan | — |
| Pratia Onkologia Katowice | Katowice, Poland | — |
| Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach, Klinika Hematologii i Transplantacji Szpiku | Kielce, Poland | — |
| Aidport Sp z o o | Skorzewo, Poland | — |
+ 7 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.